AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously ...

Acalabrutinib, a Bruton tyrosine kinase inhibitor, is currently approved under the brand name Calquence ® for MCL in patients who have received at least 1 prior therapy. It is also indicated for the ...

Acalabrutinib, a BTK inhibitor, has shown promising results in treating mantle cell lymphoma, with the FDA granting it ...

The FDA grants priority review to AZN's sNDA for Calquence for untreated mantle cell lymphoma. A decision is expected in ...

Mantle Cell Lymphoma Pipeline Report Introduction 2. Mantle Cell Lymphoma Pipeline Report Executive Summary 3. Mantle ...

AstraZeneca's supplemental New Drug Application for Calquence (acalabrutinib) has been granted Priority Review by the US FDA ...

Mantle cell lymphoma is a rare and aggressive type of non-Hodgkin lymphoma originating from B-cells in the "mantle zone" of the lymph nodes. The development of novel targeted therapies and ...

Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t(11;14). Despite its dependence on cyclin D1 ...

1 215 728 2674 Fax: +1 215 728 3639 [email protected] Mantle cell lymphoma is a unique entity of CD5 +, CD23 − B-cell lymphoma characterized by dysregulation of cyclin D1 by the translocation t ...

Geekco Technologies Corporation (the "Corporation" or "Geekco") announces that it extends until November 4, 2024 its non-brokered private placement (the "Private Placement") for which, as announced on ...

Boruzu, an injectable presentation of Velcade, has been approved by the FDA for patients who either have multiple myeloma or mantle cell lymphoma. The Food and Drug Administration (FDA) has approved ...